A systematic review of efficacy,safety and acceptability of pharmacological treatment of mixed states in bipolar disorder
10.3969/j.issn.1002-0152.2024.11.008
- VernacularTitle:双相障碍混合状态的药物治疗有效性、安全性及可接受性的系统评价
- Author:
Xiaojia HUANG
1
;
Leping HUANG
;
Yuncheng ZHU
;
Ni ZHOU
;
Jun CHEN
;
Daihui PENG
;
Yiru FANG
;
Zuowei WANG
Author Information
1. 上海市虹口区精神卫生中心,上海 200083;上海大学医学院精神卫生临床研究中心
- Publication Type:Journal Article
- Keywords:
Bipolar disorder;
Mixed states;
Mixed features;
Mixed episode;
Pharmacological treatment;
Efficacy;
Safety;
Acceptability;
Systematic review
- From:
Chinese Journal of Nervous and Mental Diseases
2024;50(11):681-687
- CountryChina
- Language:Chinese
-
Abstract:
To evaluate the efficacy,safety and acceptability of different drugs in the treatment of mixed states in bipolar disorder using the Cochrane systematic review method. The results showed that for the treatment of bipolar depression with mixed features,there is evidence to support the efficacy of lurasidone and quetiapine. Lurasidone has low metabolic and sedative side effects,and can be used in children and adolescents with bipolar depression with mixed features. Quetiapine has balanced anti-depressant and anti-manic effects,with low risk of phase transition. There is evidence to support the efficacy of olanzapine in the treatment of bipolar manic with mixed features. However,it is necessary to balance the efficacy and side effects of olanzapine,and pay attention to the risk of phase transition. For mixed episode in Bipolar disorder,aripiprazole had most research evidence. Aripiprazole has fewer side effects on metabolism and prolactin,and can be used in children with bipolar disorder. Valproate and lithium are recommended by experts for the treatment of mixed state in bipolar disorder. The inconsistency between current studies is still significant,and high-quality randomized controlled trials are urgently needed to provide more comprehensive evidence-based support for the treatment of mixed states in bipolar disorder.
